Is CANF a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Namodenoson liver-cancer (HCC) Phase 3 readout, with revenue / earnings at Pre-revenue clinical-stage company with no approved products; it reports recurring net losses, not profits. The bear case rests on this is a highly speculative micro-cap with concentrated, binary risk. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. This is a highly speculative micro-cap with concentrated, binary risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Namodenoson liver-cancer (HCC) Phase 3 readout. Namodenoson is in a pivotal Phase 3 study for advanced hepatocellular carcinoma, the program most central to Can-Fite's value, with data anticipated around late 2026.

This is a highly speculative micro-cap with concentrated, binary risk. The dominant risk is clinical failure: Can-Fite has no approved products, and negative or delayed results from the Namodenoson liver-cancer Phase 3 or the Piclidenoson psoriasis study could sharply and permanently reduce the value of the shares. Financing and dilution risk is severe: with only a few million dollars of cash and recurring annual losses, the company depends on repeated dilutive equity raises to continue operating, and the January 2026 1-for-3,000 reverse split (with ADS ratio change) reflects pressure to maintain NYSE American listing compliance, a pattern that can continue. Going-concern-type dependence on future funding means shareholders can be diluted heavily even when trials progress. Additional risks include regulatory uncertainty (FDA and other agencies may not accept the data), competition from far larger and better-capitalized drug developers, small size and thin trading that can make the ADR volatile and hard to exit, and the general reality that most clinical-stage drug candidates never reach approval. Investors should treat any position as speculative capital they can afford to lose.

Can-Fite BioPharma Ltd.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Namodenoson liver-cancer (HCC) Phase 3 readout) stalling in the reported numbers rather than in the narrative, the risk above (this is a highly speculative micro-cap with concentrated, binary risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

This is a highly speculative, binary bet, and this is not investment advice. The bull case is that positive readouts from Namodenoson (Phase 3 liver cancer) or Piclidenoson (Phase 3 psoriasis), or a licensing deal, could sharply re-rate a tiny company. The bear case is that Can-Fite has no approved products, only a few million dollars of cash, recurring losses, and a heavy reliance on dilutive financing, so a trial failure or continued dilution could cause severe loss. Because the outcome hinges on single clinical events, treat any position as speculative capital you can afford to lose.

Can-Fite is an Israeli clinical-stage biotech developing small-molecule drug candidates aimed at the A3 adenosine receptor (A3AR), a target highly expressed on inflammatory and cancer cells. Its lead candidates are Namodenoson (liver cancer, MASH liver disease, and pancreatic cancer) and Piclidenoson (psoriasis). It has no approved products and generates essentially no product revenue, so it is a research-stage company funded by capital raises.

Can-Fite is a micro-cap, pre-revenue biotech whose value depends almost entirely on clinical-trial results that are inherently uncertain and binary. It runs on a small cash balance, posts recurring losses, and relies on repeated dilutive equity raises to keep operating. A single failed or delayed trial, or continued dilution, can cause large, permanent losses, which is why it suits only risk-tolerant, speculative capital.